Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

Vaccine

Volumn 17, Issue 23-24, 1999, Pages 3145-3159

  Saul, Allan ^a   Lawrence, Gregor ^a   Smillie, Anne ^a   Rzepczyk, Christine M ^a   Reed, Carol ^a   Taylor, Darrin ^a   Anderson, Karen ^a   Stowers, Anthony ^a   Kemp, Richard ^b   Allworth, Anthony ^b   Anders, Robin F ^c   Brown, Graham V ^c   Pye, David ^d   Schoofs, Peter ^d   Irving, David O ^e   Dyer, Shanny L ^e   Woodrow, Graeme C ^e   Briggs, William R S ^f   Reber, Rosemaria ^g   Stürchler, Dieter ^g  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d CSL LIMITED   (Australia)

^e Biotechnology Australia   (Australia)

^f Saramane Pty Ltd   (Australia)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Human; Montanide ISA720; MSP1; MSP2; Plasmodium falciparum; RESA; Vaccine trial

Indexed keywords

MALARIA VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; MALARIA; NORMAL HUMAN; PARASITEMIA; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0033529701     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00175-9     Document Type: Article

References (36)

1. Engers H.D., Bergquist R., Modabber F. Progress on vaccines against parasites. Dev Biol Stand. 87:1996;73-84.
2. Lawrence G.W., Saul A., Giddy A.J., Kemp R., Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine. 15:1997;176-178.
3. Holder A.A., Freeman R.R. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature. 294:1981;361-364.
4. Siddiqui W.A., Tam L.Q., Kramer K.J., Hui G.S., Case S.E., Yamaga K.M., Chang S.P., Chan E.B., Kan S.C. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc Natl Acad Sci USA. 84:1987;3014-3018.
5. Cooper J.A., Cooper L.T., Saul A.J. Mapping of the region predominantly recognized by antibodies to the Plasmodium falciparum merozoite surface antigen MSA 1. Mol Biochem Parasitol. 51:1992;301-312.
6. Blackman M.J., Heidrich H.G., Donachie S., McBride J.S., Holder A.A. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med. 172:1990;379-382.
7. Burns J.M.J., Majarian W.R., Young J.F., Daly T.M., Long C.A. A protective monoclonal antibody recognizes an epitope in the carboxyl-terminal cysteine-rich domain in the precursor of the major merozoite surface antigen of the rodent malarial parasite, Plasmodium yoelii. J Immunol. 143:1989;2670-2676.
8. Egan A.F., Morris J., Barnish G., Allen S., Greenwood B.M., Kaslow D.C., Holder A.A., Riley E.M. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis. 173:1996;765-769.
9. Ling I.T., Ogun S.A., Holder A.A. Immunization against malaria with a recombinant protein. Parasite Immunol. 16:1994;63-67.
10. Ling I.T., Ogun S.A., Momin P., Richards R.L., Garcon N., Cohen J., Ballou W.R., Holder A.A. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. Vaccine. 15:1997;1562-1567.
11. Hirunpetcharat C., Tian J.H., Kaslow D.C., van-Rooijen N., Kumar S., Berzofsky J.A., Miller L.H., Good M.F. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T-cells. J Immunol. 159:1997;3400-3411.
12. Lew A.M., Langford C.J., Anders R.F., Kemp D.J., Saul A., Fardoulys C., Geysen M., Sheppard M. A protective monoclonal antibody recognizes a linear epitope in the precursor to the major merozoite antigens of Plasmodium chabaudi adami. Proc Natl Acad Sci USA. 86:1989;3768-3772.
13. Lew A.M., Beck D.J., Thomas L.M. A second region recognized by the protective monoclonal antibody 5C10/66 in the precursor to the major merozoite surface antigen of Plasmodium chabaudi adami. Mol Biochem Parasitol. 41:1990;289-291.
14. Herrera M.A., Rosero F., Herrera S., Caspers P., Rotmann D., Sinigaglia F., Certa U. Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection. Infect Immun. 60:1992;154-158.
15. Miller L.H., Roberts T., Shahabuddin M., McCutchan T.F. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol. 59:1993;1-14.
16. Epping R.J., Goldstone S.D., Ingram L.T., Upcroft J.A., Ramasamy R., Cooper J.A., Bushell G.R., Geysen H.M. An epitope recognised by inhibitory monoclonal antibodies that react with a 51 kilodalton merozoite surface antigen in Plasmodium falciparum. Mol Biochem Parasitol. 28:1988;1-10.
17. Saul A., Lord R., Jones G., Geysen H.M., Gale J., Mollard R. Cross-reactivity of antibody against an epitope of the Plasmodium falciparum second merozoite surface antigen. Parasite Immunol. 11:1989;593-601.
18. Saul A., Lord R., Jones G.L., Spencer L. Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2. J Immunol. 148:1992;208-211.
19. Smythe J.A., Coppel R.L., Day K.P., Martin R.K., Oduola A.M., Kemp D.J., Anders R.F. Structural diversity in the Plasmodium falciparum merozoite surface antigen 2. Proc Natl Acad Sci USA. 88:1991;1751-1755.
20. Sturchler D., Berger R., Rudin C., Just M., Saul A., Rzepczyk C., Brown G., Anders R., Coppel R., Woodrow G., Pye D., Sorenson F., Gillessen D., Matile H., Reber-Liske R. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Am J Trop Med Hyg. 53:1995;423-431.
21. Culvenor J.G., Day K.P., Anders R.F. Plasmodium falciparum ring-infected erythrocyte surface antigen is released from merozoite dense granules after erythrocyte invasion. Infect Immun. 59:1991;1183-1187.
22. Berzins K., Perlmann H., Wahlin B., Carlsson J., Wahlgren M., Udomsangpetch R., Bjorkman A., Patarroyo M.E., Perlmann P. Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf 155, react with the native protein and inhibit merozoite invasion. Proc Natl Acad Sci USA. 83:1986;1065-1069.
23. Berzins K., Perlmann H., Wahlin B., Ekre H.P., Hogh B., Petersen E., Wellde B., Schoenbechler M., Williams J., Chulay J., Perlmann P. Passive immunization of Aotus monkeys with human antibodies to the Plasmodium falciparum antigen Pf155/RESA. Infect Immun. 59:1991;1500-1506.
24. Collins W.E., Anders R.F., Pappaioanou M., Campbell G.H., Brown G.V., Kemp D.J., Coppel R.L., Skinner J.C., Andrysiak P.M., Favaloro J.M., Corcoran L.M., Broderson J.R., Mitchell G.F., Campbell C.C. Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature. 323:1986;259-262.
25. Al-Yaman F., Genton B., Anders R., Taraika J., Ginny M., Mellor S., Alpers M.P. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. Parasite Immunol. 17:1995;493-501.
26. Al-Yaman F., Genton B., Kramer K.J., Chang S.P., Hui G.S., Baisor M., Alpers M.P. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am J Trop Med Hyg. 54:1996;443-448.
27. Riley E.M., Allen S.J., Wheeler J.G., Blackman M.J., Bennett S., Takacs B., Schonfeld H.J., Holder A.A., Greenwood B.M. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol. 14:1992;321-337.
28. Al-Yaman F., Genton B., Taraika J., Anders R., Alpers M.P. Association between cellular response (IL-4) to RESA/Pf155 and protection from clinical malaria among Papua New Guinean children living in a malaria endemic area. Parasite Immunol. 19:1997;249-254.
29. Pye D., Vandenberg K.L., Dyer S.L., Irving D.O., Goss N.H., Woodrow G.C., Saul A., Alving C.R., Richards R.L., Ballou W.R., Wu M.J., Skoff K., Anders R.F. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Vaccine. 15:1997;1017-1023.
30. Favaloro J.M., Coppel R L., Corcoran L.M., Foote S.J., Brown G.V., Anders R.F., Kemp D.J. Structure of the RESA gene of Plasmodium falciparum. Nucleic Acids Res. 14:1986;8265-8277.
31. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 83:1977;346-356.
32. Rzepczyk C.M., Ramasamy R., Ho P.C., Mutch D.A., Anderson K.L., Duggleby R.G., Doran T.J., Murray B.J., Irving D.O., Woodrow G.C., Parkinson D., Brabin B.J., Alpers M.P. Identification of T epitopes within a potential Plasmodium falciparum vaccine antigen. A study of human lymphocyte responses to repeat and nonrepeat regions of Pf155/RESA. J Immunol. 141:1988;3197-3202.
33. Saul A. Kinetic constraints on the development of a malaria vaccine. Parasite Immunol. 9:1987;1-9.
34. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., Wellde B T., Garcon N., Krzych U., Marchand M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 336:1997;86-91.
35. Kumaratilake L.M., Ferrante A., Jaeger T., Rzepczyk C.M. Effects of cytokines, complement, and antibody on the neutrophil respiratory burst and phagocytic response to Plasmodium falciparum merozoites. Infect Immun. 60:1992;3731-3738.
36. Bouharoun T.H., Oeuvray C., Lunel F., Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med. 182:1995;409-418.